Dept of Paediatric Respiratory Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Dept of Paediatrics, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.
Eur Respir J. 2018 Jun 7;51(6). doi: 10.1183/13993003.02509-2017. Print 2018 Jun.
To identify potential risk factors for lung disease progression in children with cystic fibrosis (CF), we studied the longitudinal data of all children with CF (aged ≥5 years) registered in the Dutch CF Registry (2009-2014).Lung disease progression was expressed as a decline in lung function (forced expiratory volume in 1 s (FEV) % pred) and pulmonary exacerbation rate. Potential risk factors at baseline included sex, age, best FEV % pred, best forced vital capacity % pred, genotype, body mass index z-score, pancreatic insufficiency, medication use (proton pump inhibitors (PPIs), prophylactic antibiotics and inhaled corticosteroids), CF-related diabetes, allergic bronchopulmonary aspergillosis and colonisation with The data of 545 children were analysed. PPI use was associated with both annual decline of FEV % pred (p=0.017) and future pulmonary exacerbation rate (p=0.006). Moreover, lower FEV % pred at baseline (p=0.007), prophylactic inhaled antibiotic use (p=0.006) and pulmonary exacerbations in the baseline year (p=0.002) were related to pulmonary exacerbations in subsequent years.In a cohort of Dutch children with CF followed for 5 years, we were able to identify several risk factors for future exacerbations. In particular, the association between PPI use and lung disease progression definitely requires further investigation.
为了确定囊性纤维化(CF)患儿肺部疾病进展的潜在风险因素,我们研究了荷兰 CF 登记处(2009-2014 年)登记的所有年龄≥5 岁的 CF 患儿的纵向数据。肺部疾病进展用肺功能(1 秒用力呼气量(FEV)%预计值)和肺部恶化率下降来表示。基线时的潜在危险因素包括性别、年龄、最佳 FEV %预计值、最佳用力肺活量%预计值、基因型、体重指数 z 分数、胰腺功能不全、药物使用(质子泵抑制剂(PPIs)、预防性抗生素和吸入性皮质类固醇)、CF 相关糖尿病、过敏性支气管曲霉病和定植。对 545 名儿童的数据进行了分析。PPI 使用与 FEV %预计值的年下降(p=0.017)和未来肺部恶化率(p=0.006)有关。此外,基线时较低的 FEV %预计值(p=0.007)、预防性吸入抗生素使用(p=0.006)和基线年的肺部恶化(p=0.002)与随后几年的肺部恶化有关。在对荷兰 CF 患儿进行的 5 年随访队列中,我们能够确定未来恶化的几个风险因素。特别是,PPI 使用与肺部疾病进展之间的关联确实需要进一步研究。